Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices

Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells toward a profibrotic phenotype. Collagens, an important part of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in pharmacology 2021-07, Vol.12, p.669037-669037, Article 669037
Hauptverfasser: Vasse, Gwenda F., Van Os, Lisette, De Jager, Marina, Jonker, Marnix R., Borghuis, Theo, Van den Toorn, L. Tim, Jellema, Pytrick, White, Eric S., Van Rijn, Patrick, Harmsen, Martin C., Heijink, Irene H., Melgert, Barbro N., Burgess, Janette K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 669037
container_issue
container_start_page 669037
container_title Frontiers in pharmacology
container_volume 12
creator Vasse, Gwenda F.
Van Os, Lisette
De Jager, Marina
Jonker, Marnix R.
Borghuis, Theo
Van den Toorn, L. Tim
Jellema, Pytrick
White, Eric S.
Van Rijn, Patrick
Harmsen, Martin C.
Heijink, Irene H.
Melgert, Barbro N.
Burgess, Janette K.
description Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells toward a profibrotic phenotype. Collagens, an important part of the fibrotic ECM, have been shown to be structurally different in IPF. To further understand the disease to develop better treatments, the signals from the ECM that drive fibrosis need to be identified. Adipose tissue-derived stromal cell conditioned medium (ASC-CM) has demonstrated antifibrotic effects in animal studies but has not been tested in human samples yet. In this study, the collagen structural integrity in (fibrotic) lung tissue, its interactions with fibroblasts and effects of ASC-CM treatment hereon were studied. Methods: Native and decellularized lung tissue from patients with IPF and controls were stained for denatured collagen using a collagen hybridizing peptide. Primary lung fibroblasts were seeded into decellularized matrices from IPF and control subjects and cultured for 7 days in the presence or absence of ASC- CM. Reseeded matrices were fixed, stained and analyzed for total tissue deposition and specific protein expression. Results: In both native and decellularized lung tissue, more denatured collagen was observed in IPF tissue compared to control tissue. Upon recellularization with fibroblasts, the presence of denatured collagen was equalized in IPF and control matrices, whereas total ECM was higher in IPF matrices than in the control. Treatment with ASC-CM resulted in less ECM deposition, but did not alter the levels of denatured collagen. Discussion: Our data showed that ASC-CM can inhibit fibrotic ECM-induced profibrotic behavior of fibroblasts. This process was independent of collagen structural integrity. Our findings open up new avenues for ASC-CM to be explored as treatment for IPF.
doi_str_mv 10.3389/fphar.2021.669037
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000683864000001CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_2ad3140a7bce4d829fc6429caec51692</doaj_id><sourcerecordid>2561916314</sourcerecordid><originalsourceid>FETCH-LOGICAL-c465t-b32a2e9d3478c46d7c4f6afc878bd7baaee265e025364ffa30a0e0bdbf6c1dcb3</originalsourceid><addsrcrecordid>eNqNkl9v0zAUxSMEYtPYB-AF5REJtfhP4tgvSFNFoVIRk8qerRvnuvOUxMV2QHx73GZU2xt-sXXvOcdX_rko3lKy5Fyqj_ZwD2HJCKNLIRThzYvikgrBF0pS9vLJ-aK4jvGB5MWV4qJ6XVzwiiveNPSyuLvp3MFHLHcp-AH6coV9v9ihCZj8gOXKT2PCACbF8jZ469rgkzPlzu1H6GO5zq5yc7sut9O4L79BCs5gfFO8srmL14_7VXG3_vxj9XWx_f5ls7rZLkwl6rRoOQOGquNVI3Ola0xlBVgjG9l2TQuAyESNhNV5bGuBEyBI2q61wtDOtPyq2My5nYcHfQhugPBHe3D6VPBhryHkcXvUDDpOKwJNa7DqJFPWiIopA2hqKhTLWZ_mrMPUDtgZHFOA_lno887o7vXe_9KS17WSMge8fwwI_ueEMenBRZOfE0b0U9SsFlRRkafIUjpLTfAxBrTnayjRR7r6RFcf6eqZbva8ezrf2fGPZRbIWfAbW2-jcTgaPMsyfiG5FNXxIxC6cgmS8-OJb7Z--H8r_wua5cQZ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2561916314</pqid></control><display><type>article</type><title>Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>PubMed Central</source><creator>Vasse, Gwenda F. ; Van Os, Lisette ; De Jager, Marina ; Jonker, Marnix R. ; Borghuis, Theo ; Van den Toorn, L. Tim ; Jellema, Pytrick ; White, Eric S. ; Van Rijn, Patrick ; Harmsen, Martin C. ; Heijink, Irene H. ; Melgert, Barbro N. ; Burgess, Janette K.</creator><creatorcontrib>Vasse, Gwenda F. ; Van Os, Lisette ; De Jager, Marina ; Jonker, Marnix R. ; Borghuis, Theo ; Van den Toorn, L. Tim ; Jellema, Pytrick ; White, Eric S. ; Van Rijn, Patrick ; Harmsen, Martin C. ; Heijink, Irene H. ; Melgert, Barbro N. ; Burgess, Janette K.</creatorcontrib><description>Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells toward a profibrotic phenotype. Collagens, an important part of the fibrotic ECM, have been shown to be structurally different in IPF. To further understand the disease to develop better treatments, the signals from the ECM that drive fibrosis need to be identified. Adipose tissue-derived stromal cell conditioned medium (ASC-CM) has demonstrated antifibrotic effects in animal studies but has not been tested in human samples yet. In this study, the collagen structural integrity in (fibrotic) lung tissue, its interactions with fibroblasts and effects of ASC-CM treatment hereon were studied. Methods: Native and decellularized lung tissue from patients with IPF and controls were stained for denatured collagen using a collagen hybridizing peptide. Primary lung fibroblasts were seeded into decellularized matrices from IPF and control subjects and cultured for 7 days in the presence or absence of ASC- CM. Reseeded matrices were fixed, stained and analyzed for total tissue deposition and specific protein expression. Results: In both native and decellularized lung tissue, more denatured collagen was observed in IPF tissue compared to control tissue. Upon recellularization with fibroblasts, the presence of denatured collagen was equalized in IPF and control matrices, whereas total ECM was higher in IPF matrices than in the control. Treatment with ASC-CM resulted in less ECM deposition, but did not alter the levels of denatured collagen. Discussion: Our data showed that ASC-CM can inhibit fibrotic ECM-induced profibrotic behavior of fibroblasts. This process was independent of collagen structural integrity. Our findings open up new avenues for ASC-CM to be explored as treatment for IPF.</description><identifier>ISSN: 1663-9812</identifier><identifier>EISSN: 1663-9812</identifier><identifier>DOI: 10.3389/fphar.2021.669037</identifier><identifier>PMID: 34393771</identifier><language>eng</language><publisher>LAUSANNE: Frontiers Media Sa</publisher><subject>adipose tissue-derived stromal/stem cells (ASCs) ; collagen hybridizing peptide ; decellularized lung matrices ; denatured collagen ; extracellular matrix (ECM) ; idiopathic pulmonary fibrosis (IPF) ; Life Sciences &amp; Biomedicine ; Pharmacology ; Pharmacology &amp; Pharmacy ; Science &amp; Technology</subject><ispartof>Frontiers in pharmacology, 2021-07, Vol.12, p.669037-669037, Article 669037</ispartof><rights>Copyright © 2021 Vasse, Van Os, De Jager, Jonker, Borghuis, Van Den Toorn, Jellema, White, Van Rijn, Harmsen, Heijink, Melgert and Burgess.</rights><rights>Copyright © 2021 Vasse, Van Os, De Jager, Jonker, Borghuis, Van Den Toorn, Jellema, White, Van Rijn, Harmsen, Heijink, Melgert and Burgess. 2021 Vasse, Van Os, De Jager, Jonker, Borghuis, Van Den Toorn, Jellema, White, Van Rijn, Harmsen, Heijink, Melgert and Burgess</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>7</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000683864000001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c465t-b32a2e9d3478c46d7c4f6afc878bd7baaee265e025364ffa30a0e0bdbf6c1dcb3</citedby><cites>FETCH-LOGICAL-c465t-b32a2e9d3478c46d7c4f6afc878bd7baaee265e025364ffa30a0e0bdbf6c1dcb3</cites><orcidid>0000-0002-7128-2741 ; 0000-0003-3623-7045 ; 0000-0001-6309-871X ; 0000-0001-9868-9966 ; 0000-0003-4060-8443</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355988/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8355988/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,729,782,786,866,887,2104,2116,27931,27932,39265,53798,53800</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34393771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vasse, Gwenda F.</creatorcontrib><creatorcontrib>Van Os, Lisette</creatorcontrib><creatorcontrib>De Jager, Marina</creatorcontrib><creatorcontrib>Jonker, Marnix R.</creatorcontrib><creatorcontrib>Borghuis, Theo</creatorcontrib><creatorcontrib>Van den Toorn, L. Tim</creatorcontrib><creatorcontrib>Jellema, Pytrick</creatorcontrib><creatorcontrib>White, Eric S.</creatorcontrib><creatorcontrib>Van Rijn, Patrick</creatorcontrib><creatorcontrib>Harmsen, Martin C.</creatorcontrib><creatorcontrib>Heijink, Irene H.</creatorcontrib><creatorcontrib>Melgert, Barbro N.</creatorcontrib><creatorcontrib>Burgess, Janette K.</creatorcontrib><title>Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices</title><title>Frontiers in pharmacology</title><addtitle>FRONT PHARMACOL</addtitle><addtitle>Front Pharmacol</addtitle><description>Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells toward a profibrotic phenotype. Collagens, an important part of the fibrotic ECM, have been shown to be structurally different in IPF. To further understand the disease to develop better treatments, the signals from the ECM that drive fibrosis need to be identified. Adipose tissue-derived stromal cell conditioned medium (ASC-CM) has demonstrated antifibrotic effects in animal studies but has not been tested in human samples yet. In this study, the collagen structural integrity in (fibrotic) lung tissue, its interactions with fibroblasts and effects of ASC-CM treatment hereon were studied. Methods: Native and decellularized lung tissue from patients with IPF and controls were stained for denatured collagen using a collagen hybridizing peptide. Primary lung fibroblasts were seeded into decellularized matrices from IPF and control subjects and cultured for 7 days in the presence or absence of ASC- CM. Reseeded matrices were fixed, stained and analyzed for total tissue deposition and specific protein expression. Results: In both native and decellularized lung tissue, more denatured collagen was observed in IPF tissue compared to control tissue. Upon recellularization with fibroblasts, the presence of denatured collagen was equalized in IPF and control matrices, whereas total ECM was higher in IPF matrices than in the control. Treatment with ASC-CM resulted in less ECM deposition, but did not alter the levels of denatured collagen. Discussion: Our data showed that ASC-CM can inhibit fibrotic ECM-induced profibrotic behavior of fibroblasts. This process was independent of collagen structural integrity. Our findings open up new avenues for ASC-CM to be explored as treatment for IPF.</description><subject>adipose tissue-derived stromal/stem cells (ASCs)</subject><subject>collagen hybridizing peptide</subject><subject>decellularized lung matrices</subject><subject>denatured collagen</subject><subject>extracellular matrix (ECM)</subject><subject>idiopathic pulmonary fibrosis (IPF)</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Pharmacology</subject><subject>Pharmacology &amp; Pharmacy</subject><subject>Science &amp; Technology</subject><issn>1663-9812</issn><issn>1663-9812</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>DOA</sourceid><recordid>eNqNkl9v0zAUxSMEYtPYB-AF5REJtfhP4tgvSFNFoVIRk8qerRvnuvOUxMV2QHx73GZU2xt-sXXvOcdX_rko3lKy5Fyqj_ZwD2HJCKNLIRThzYvikgrBF0pS9vLJ-aK4jvGB5MWV4qJ6XVzwiiveNPSyuLvp3MFHLHcp-AH6coV9v9ihCZj8gOXKT2PCACbF8jZ469rgkzPlzu1H6GO5zq5yc7sut9O4L79BCs5gfFO8srmL14_7VXG3_vxj9XWx_f5ls7rZLkwl6rRoOQOGquNVI3Ola0xlBVgjG9l2TQuAyESNhNV5bGuBEyBI2q61wtDOtPyq2My5nYcHfQhugPBHe3D6VPBhryHkcXvUDDpOKwJNa7DqJFPWiIopA2hqKhTLWZ_mrMPUDtgZHFOA_lno887o7vXe_9KS17WSMge8fwwI_ueEMenBRZOfE0b0U9SsFlRRkafIUjpLTfAxBrTnayjRR7r6RFcf6eqZbva8ezrf2fGPZRbIWfAbW2-jcTgaPMsyfiG5FNXxIxC6cgmS8-OJb7Z--H8r_wua5cQZ</recordid><startdate>20210728</startdate><enddate>20210728</enddate><creator>Vasse, Gwenda F.</creator><creator>Van Os, Lisette</creator><creator>De Jager, Marina</creator><creator>Jonker, Marnix R.</creator><creator>Borghuis, Theo</creator><creator>Van den Toorn, L. Tim</creator><creator>Jellema, Pytrick</creator><creator>White, Eric S.</creator><creator>Van Rijn, Patrick</creator><creator>Harmsen, Martin C.</creator><creator>Heijink, Irene H.</creator><creator>Melgert, Barbro N.</creator><creator>Burgess, Janette K.</creator><general>Frontiers Media Sa</general><general>Frontiers Media S.A</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7128-2741</orcidid><orcidid>https://orcid.org/0000-0003-3623-7045</orcidid><orcidid>https://orcid.org/0000-0001-6309-871X</orcidid><orcidid>https://orcid.org/0000-0001-9868-9966</orcidid><orcidid>https://orcid.org/0000-0003-4060-8443</orcidid></search><sort><creationdate>20210728</creationdate><title>Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices</title><author>Vasse, Gwenda F. ; Van Os, Lisette ; De Jager, Marina ; Jonker, Marnix R. ; Borghuis, Theo ; Van den Toorn, L. Tim ; Jellema, Pytrick ; White, Eric S. ; Van Rijn, Patrick ; Harmsen, Martin C. ; Heijink, Irene H. ; Melgert, Barbro N. ; Burgess, Janette K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c465t-b32a2e9d3478c46d7c4f6afc878bd7baaee265e025364ffa30a0e0bdbf6c1dcb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>adipose tissue-derived stromal/stem cells (ASCs)</topic><topic>collagen hybridizing peptide</topic><topic>decellularized lung matrices</topic><topic>denatured collagen</topic><topic>extracellular matrix (ECM)</topic><topic>idiopathic pulmonary fibrosis (IPF)</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Pharmacology</topic><topic>Pharmacology &amp; Pharmacy</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vasse, Gwenda F.</creatorcontrib><creatorcontrib>Van Os, Lisette</creatorcontrib><creatorcontrib>De Jager, Marina</creatorcontrib><creatorcontrib>Jonker, Marnix R.</creatorcontrib><creatorcontrib>Borghuis, Theo</creatorcontrib><creatorcontrib>Van den Toorn, L. Tim</creatorcontrib><creatorcontrib>Jellema, Pytrick</creatorcontrib><creatorcontrib>White, Eric S.</creatorcontrib><creatorcontrib>Van Rijn, Patrick</creatorcontrib><creatorcontrib>Harmsen, Martin C.</creatorcontrib><creatorcontrib>Heijink, Irene H.</creatorcontrib><creatorcontrib>Melgert, Barbro N.</creatorcontrib><creatorcontrib>Burgess, Janette K.</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vasse, Gwenda F.</au><au>Van Os, Lisette</au><au>De Jager, Marina</au><au>Jonker, Marnix R.</au><au>Borghuis, Theo</au><au>Van den Toorn, L. Tim</au><au>Jellema, Pytrick</au><au>White, Eric S.</au><au>Van Rijn, Patrick</au><au>Harmsen, Martin C.</au><au>Heijink, Irene H.</au><au>Melgert, Barbro N.</au><au>Burgess, Janette K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices</atitle><jtitle>Frontiers in pharmacology</jtitle><stitle>FRONT PHARMACOL</stitle><addtitle>Front Pharmacol</addtitle><date>2021-07-28</date><risdate>2021</risdate><volume>12</volume><spage>669037</spage><epage>669037</epage><pages>669037-669037</pages><artnum>669037</artnum><issn>1663-9812</issn><eissn>1663-9812</eissn><abstract>Introduction: Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease characterized by excess deposition and altered structure of extracellular matrix (ECM) in the lungs. The fibrotic ECM is paramount in directing resident cells toward a profibrotic phenotype. Collagens, an important part of the fibrotic ECM, have been shown to be structurally different in IPF. To further understand the disease to develop better treatments, the signals from the ECM that drive fibrosis need to be identified. Adipose tissue-derived stromal cell conditioned medium (ASC-CM) has demonstrated antifibrotic effects in animal studies but has not been tested in human samples yet. In this study, the collagen structural integrity in (fibrotic) lung tissue, its interactions with fibroblasts and effects of ASC-CM treatment hereon were studied. Methods: Native and decellularized lung tissue from patients with IPF and controls were stained for denatured collagen using a collagen hybridizing peptide. Primary lung fibroblasts were seeded into decellularized matrices from IPF and control subjects and cultured for 7 days in the presence or absence of ASC- CM. Reseeded matrices were fixed, stained and analyzed for total tissue deposition and specific protein expression. Results: In both native and decellularized lung tissue, more denatured collagen was observed in IPF tissue compared to control tissue. Upon recellularization with fibroblasts, the presence of denatured collagen was equalized in IPF and control matrices, whereas total ECM was higher in IPF matrices than in the control. Treatment with ASC-CM resulted in less ECM deposition, but did not alter the levels of denatured collagen. Discussion: Our data showed that ASC-CM can inhibit fibrotic ECM-induced profibrotic behavior of fibroblasts. This process was independent of collagen structural integrity. Our findings open up new avenues for ASC-CM to be explored as treatment for IPF.</abstract><cop>LAUSANNE</cop><pub>Frontiers Media Sa</pub><pmid>34393771</pmid><doi>10.3389/fphar.2021.669037</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-7128-2741</orcidid><orcidid>https://orcid.org/0000-0003-3623-7045</orcidid><orcidid>https://orcid.org/0000-0001-6309-871X</orcidid><orcidid>https://orcid.org/0000-0001-9868-9966</orcidid><orcidid>https://orcid.org/0000-0003-4060-8443</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1663-9812
ispartof Frontiers in pharmacology, 2021-07, Vol.12, p.669037-669037, Article 669037
issn 1663-9812
1663-9812
language eng
recordid cdi_webofscience_primary_000683864000001CitationCount
source DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; PubMed Central
subjects adipose tissue-derived stromal/stem cells (ASCs)
collagen hybridizing peptide
decellularized lung matrices
denatured collagen
extracellular matrix (ECM)
idiopathic pulmonary fibrosis (IPF)
Life Sciences & Biomedicine
Pharmacology
Pharmacology & Pharmacy
Science & Technology
title Adipose Stromal Cell-Secretome Counteracts Profibrotic Signals From IPF Lung Matrices
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T23%3A06%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adipose%20Stromal%20Cell-Secretome%20Counteracts%20Profibrotic%20Signals%20From%20IPF%20Lung%20Matrices&rft.jtitle=Frontiers%20in%20pharmacology&rft.au=Vasse,%20Gwenda%20F.&rft.date=2021-07-28&rft.volume=12&rft.spage=669037&rft.epage=669037&rft.pages=669037-669037&rft.artnum=669037&rft.issn=1663-9812&rft.eissn=1663-9812&rft_id=info:doi/10.3389/fphar.2021.669037&rft_dat=%3Cproquest_webof%3E2561916314%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2561916314&rft_id=info:pmid/34393771&rft_doaj_id=oai_doaj_org_article_2ad3140a7bce4d829fc6429caec51692&rfr_iscdi=true